Evidence map›Paper›PMID 41681841›Full record

ArticleCancers2026

Antitumor Effects of Broadleaf Vetch Against Esophageal Squamous Cell Carcinoma Through Dual Mechanisms: Suppressing EMT and Inducing Ferroptosis with Predicted Hepatorenal Toxicity-An Integrative Network Pharmacology and Toxicology Study.

Yuxuan Xing, Siao Chen, Kang Hu, Zihan Cui, Yuhan Shao, Jingfeng Zhu, Zhimeng Chen, Jun Chen, Weijun Deng, Cheng Ding and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yuxuan XingInstitute of Minimally Invasive Thoracic Cancer Therapy and Translational Research, Suzhou Medical College, Soochow University, Suzhou 215000, China.
Siao ChenInstitute of Minimally Invasive Thoracic Cancer Therapy and Translational Research, Suzhou Medical College, Soochow University, Suzhou 215000, China.
Kang HuInstitute of Minimally Invasive Thoracic Cancer Therapy and Translational Research, Suzhou Medical College, Soochow University, Suzhou 215000, China.
Zihan CuiInstitute of Minimally Invasive Thoracic Cancer Therapy and Translational Research, Suzhou Medical College, Soochow University, Suzhou 215000, China.
Yuhan ShaoInstitute of Minimally Invasive Thoracic Cancer Therapy and Translational Research, Suzhou Medical College, Soochow University, Suzhou 215000, China.
Jingfeng ZhuInstitute of Minimally Invasive Thoracic Cancer Therapy and Translational Research, Suzhou Medical College, Soochow University, Suzhou 215000, China.
Zhimeng ChenInstitute of Minimally Invasive Thoracic Cancer Therapy and Translational Research, Suzhou Medical College, Soochow University, Suzhou 215000, China.ORCID 0009-0003-7841-9207
Jun ChenInstitute of Minimally Invasive Thoracic Cancer Therapy and Translational Research, Suzhou Medical College, Soochow University, Suzhou 215000, China.
Weijun DengInstitute of Minimally Invasive Thoracic Cancer Therapy and Translational Research, Suzhou Medical College, Soochow University, Suzhou 215000, China.
Cheng DingInstitute of Minimally Invasive Thoracic Cancer Therapy and Translational Research, Suzhou Medical College, Soochow University, Suzhou 215000, China.
Jun ZhaoInstitute of Minimally Invasive Thoracic Cancer Therapy and Translational Research, Suzhou Medical College, Soochow University, Suzhou 215000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEsophageal squamous cell carcinoma (ESCC) remains a highly lethal malignancy with limited effective treatments. Broadleaf Vetch (

methodsNetwork pharmacology was used to identify BV-related therapeutic targets and pathways. Molecular docking validated interactions between BV components and core proteins. In vitro assays evaluated proliferation, colony formation, migration, invasion, epithelial-mesenchymal transition (EMT) markers, and ferroptosis-related indices. An ESCC xenograft model was used to assess antitumor efficacy in vivo.

resultsFive major BV components and 363 ESCC-related targets were identified, highlighting the PI3K-AKT pathway and key nodes such as EGFR, AKT1, SRC, TP53, and GPX4. BV significantly inhibited ESCC cell proliferation, migration, and invasion, and reversed EMT marker expression. Ferroptosis induction was evidenced by significant Fe

conclusionsBV exerts dual antitumor effects in ESCC by suppressing EMT and inducing ferroptosis. These findings suggest BV may represent a potential multi-target phytotherapeutic candidate for ESCC.

Indexed as

broadleaf vetchesophageal squamous cell carcinomaferroptosishepatotoxicitynephrotoxicitynetwork pharmacology

Identifiers

PMID41681841
PMCPMC12897322

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.